Skip to content

Cannabis: all studies

Page 245 of 287: studies 2,441 to 2,450 of 2,864, newest first. Back to the cannabis overview

Research

Interpellations and challenges in the neoshamanic and ayahuasca fields in Uruguay

February 15, 2018 Juan Scuro 10 citations

Since the 1990s, three major (neo)shamanic linages associated with sacred plants use have arrived in Uruguay. Each one comes from a particular Latin American national context: Brazil and its ayahuasca religions, Peru and vegetalismo, Mexico and the Red Path. In what way do these practices and discourses develop in a Latin American country imagined as "white," "without indigenous people," and...

Spirit and being: interdisciplinary reflections on drugs across history and politics

Third World Quarterly February 1, 2018 Maziyar Ghiabi 32 citations

Few commodities are as global as drugs. Cannabis, opium, heroin, amphetamines, lysergic acid diethylamide (LSD), khat, psychedelic cacti and mushrooms as well as an interminable list of other natural or synthesised substances travel and are consumed around the globe for all possible reasons. Human migration, trade, cultural trends, medical practice, political repression: together they...

Music festival attendees' illicit drug use, knowledge and practices regarding drug content and purity: a cross-sectional survey.

Harm Reduction Journal January 5, 2018 Niamh Day, Joshua Criss, Benjamin J Griffiths et al.

Drug checking is a harm reduction strategy which allows users to check the content and purity of illicit drugs. Although drug checking has been trialled internationally, with demonstrated value as a harm reduction and health promotion strategy, the use of such services in Australia remains a contentious issue. This study aimed to investigate the proportion and patterns of illicit drug use among...

A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products.

PLoS One 2018 Qingfang Meng, Beth Buchanan, Jonathan Zuccolo et al.

In the past 50 years, Cannabis sativa (C. sativa) has gone from a substance essentially prohibited worldwide to one that is gaining acceptance both culturally and legally in many countries for medicinal and recreational use. As additional jurisdictions legalize Cannabis products and the variety and complexity of these products surpass the classical dried plant material, appropriate methods for...

Discriminative Stimulus Properties of Phytocannabinoids, Endocannabinoids, and Synthetic Cannabinoids.

Current Topics in Behavioral Neurosciences 2018 Jenny L Wiley, R Allen Owens, Aron H Lichtman

Psychoactive cannabinoids from the marijuana plant (phytocannabinoids), from the body (endocannabinoids), and from the research lab (synthetic cannabinoids) produce their discriminative stimulus effects by stimulation of CB1 receptors in the brain. Early discrimination work with phytocannabinoids confirmed that Δ9-tetrahydrocannabinol (Δ9-THC) is the primary psychoactive constituent of the...

DOI: 10.1007/7854_2016_24 (opens in new tab) Full text (opens in new tab) 2-arachidonoylglycerol Anandamide Endocannabinoids Faah inhibitors +3

Intracerebral Hemorrhage with Multiple Intracranial Arterial Stenoses in a Synthetic Cannabinoid "Spice" User.

Asian journal of neurosurgery 2018 Seckin Aydin, Odhan Yuksel, Aysegul Esen Aydin et al.

Synthetic cannabinoids (spice), which are used frequently worldwide, are more potent than herbal compounds and also have more side effects in comparison. A 23-year-old male was admitted to the emergency unit with altered consciousness. There was no sign of trauma, and his medical history did not reveal any chronic illness. Computed tomography revealed a large frontal hematoma extending to the...

DOI: 10.4103/ajns.ajns_48_16 (opens in new tab) Full text (opens in new tab) Intracerebral hemorrhage Side effect Synthetic cannabinoid

The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.

Handbook of experimental pharmacology 2018 Samuel D Banister, Mark Connor

Synthetic cannabinoid receptor agonists (SCRAs) have proliferated as new psychoactive substances (NPS) over the past decade. Relative to other classes of NPS, SCRAs are structurally heterogeneous; however, most SCRAs act as potent, high-efficacy agonists of cannabinoid type 1 and type 2 receptors (CB1 and CB2, respectively). Characterization of the pharmacology and toxicology of these...

Role of the Cannabinoid System in the Limbic System

The Neuroscience Journal of Shefaye Khatam 2018 Maryam Azimi, Parastoo Barati Dowom, Khadijeh Abdal et al. 1 citation

Introduction:The limbic system plays an important role in neural mechanisms related to emotion and memory.Hallucinogenic drugs are a factor affecting the functioning of this system and interfering with its nervous system regulation.Recent studies on adolescent users of hallucinogenic drugs, such as marijuana, have shown some degree of behavioral and emotional disorders.Cannabinoids, compounds...

Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review.

Frontiers in Psychiatry 2018 Jennifer L Jones, Camilo F Mateus, Robert J Malcolm et al.

Background: Despite advances in behavioral and pharmacotherapy interventions, substance use disorders (SUDs) are frequently refractory to treatment. Glutamatergic dysregulation has received increasing attention as one common neuropathology across multiple substances of abuse. Ketamine is a potent N-methyl-D-aspartate (NMDA) glutamatergic receptor antagonist which has been found to be effective...

Anomalous Self-Experiences: Markers of Schizophrenia Vulnerability or Symptoms of Depersonalization Disorder? A Phenomenological Investigation of Two Cases.

Psychopathology 2018 Tor Gunnar Værnes, Jan Ivar Røssberg, Paul Møller

Basic self-disturbance (BSD) is proposed to constitute the clinical core of schizophrenia spectrum disorders, including prodromal states and schizotypy. Anomalous self-experiences (ASEs) are suggested as phenotypic variants of BSD, representing markers of schizophrenia vulnerability. However, ASEs are not restricted to the schizophrenia spectrum, but may also occur in non-psychotic states like...

DOI: 10.1159/000488462 (opens in new tab) Full text (opens in new tab) Anomalous self-experiences Basic self-disturbance Depersonalization disorder Schizophrenia spectrum disorders +2